Zentalis Pharmaceuticals ZNTL 深 沪

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals granted 191,000 non-qualified stock options to two new employees on June 1, 2026, under its 2022 Inducement Plan. The options, with an exercise price of $3.98 per share, vest over four years and are subject to continued employment. Zentalis is a clinical oncology company advancing a first-in-class WEE1 inhibitor for ovarian cancer treatment.

06-01 21:00

Zentalis Pharmaceuticals To Reveal Its Phase 1b MUIR Trial Data Showing Clinical Activity And Manageable Safety Profile of Azenosertib Plus Paclitaxel In Platinum-Resistant Ovarian Cancer At ASCO 2026; Activity Of The Combined Regimen Across All Dose Cohorts Achieved 39% ORR And 7.3-Month Median PFS;

Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for

05-22 05:45

Zentalis Pharma Q1 EPS $(0.50) Misses $(0.47) Estimate

Zentalis Pharma (NASDAQ:ZNTL) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.47) by 6.38 percent. This is a 25.37 percent increase over losses of $(0.67) per share from

05-13 05:18

Zentalis Advances Azenosertib with New Trial Updates

Zentalis Pharmaceuticals ( ($ZNTL) ) has provided an announcement. On May 12, 2...

05-13 04:49

Zentalis Pharmaceuticals Doses First Patient In Phase 3 ASPENOVA Clinical Trial

Global Phase 3, randomized, controlled trial comparing azenosertib to standard-of-care chemotherapy now enrollingASPENOVA designed as confirmatory study to support DENALI Phase 2 accelerated approval pathway, pending FDA

05-05 20:10

Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

05-05 12:00

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals granted 26,000 non-qualified stock options to a newly hired employee under its 2022 Inducement Plan. The options, exercisable at $4.09 per share, vest over four years with 25% after one year and the remaining 75% in monthly installments over the next three years, contingent on continued employment. Zentalis is a clinical oncology company focused on developing a first-in-class WEE1 inhibitor for ovarian cancer treatment.

05-01 21:30

Zentalis Pharmaceuticals Announces Data Presented From Two Posters Regarding Preclinical Activity Of Azenosertib In Triple-Negative Breast Cancer At 2026 American Association For Cancer Research

Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment

04-18 03:20

Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026

04-17 19:15

美股大行评级 | 大砍54%！大摩下调Robinhood 目标价从147降至95美元；星座品牌酒业(STZ)获8家大行上调目标价

今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从9.5美元升至9.75美元；Citizens：维持戴夫"跑赢大市"评级，目标价从310美元升至335美元

04-13 14:07